Related references
Note: Only part of the references are listed.Sialylation of vasorin by ST3Gal1 facilitates TGF-β1-mediated tumor angiogenesis and progression
Hui Ling Yeo et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
Heng-Huan Lee et al.
CANCER CELL (2019)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells
Tan-Chi Fan et al.
CANCER LETTERS (2018)
Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer
Xin Wu et al.
CELL DEATH & DISEASE (2018)
CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity
Yu Wang et al.
ONCOLOGY LETTERS (2017)
Increasing the depth of mass spectrometry-based glycomic coverage by additional dimensions of sulfoglycomics and target analysis of permethylated glycans
Ping-Fu Cheng et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2013)
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
S. Bellone et al.
BRITISH JOURNAL OF CANCER (2012)
Consequences of the expression of sialylated antigens in breast cancer
Aurelie Cazet et al.
CARBOHYDRATE RESEARCH (2010)
Over-expression of ST3Gal-I promotes mammary tumorigenesis
Gianfranco Picco et al.
GLYCOBIOLOGY (2010)
From structural to functional glycomics: core substitutions as molecular switches for shape and lectin affinity of N-glycans
Sabine Andre et al.
BIOLOGICAL CHEMISTRY (2009)
Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack
S. Zell et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
Complement decay accelerating factor (DAF)/CD55 in cancer
I Spendlove et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites
K Julenius et al.
GLYCOBIOLOGY (2005)
Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid
N Donin et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2003)
Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds
RG Spiro
GLYCOBIOLOGY (2002)
The human sialyltransferase family
A Harduin-Lepers et al.
BIOCHIMIE (2001)
Advances in immunology: Complement (First of two parts).
MJ Walport
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Polymorphic expression of decay-accelerating factor in human colorectal cancer
M Nakagawa et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2001)
Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1
D Hourcade et al.
IMMUNOPHARMACOLOGY (2000)
Share Paper
